Mr. Dayton Misfeldt is a Partner at Decheng Capital and has been with the firm since January 2021.
Prior to joining Decheng Capital, Mr. Misfeldt was a Managing Director of Bay City Capital. At Bay City Capital, Mr. Misfeldt invested in biopharmaceutical companies and worked closely with management teams on strategic decision making, business development and positioning companies for exit opportunities through accessing the public markets or acquisition. Past investments include Cadence Pharmaceuticals (acquired by Mallinckrodt), Civitas Therapeutics (acquired by Acorda Therapeutics), Dermira (acquired by Eli Lilly), MAP Pharmaceuticals (acquired by Allergan), Nextwave Pharmaceuticals (acquired by Pfizer), Oculex Pharmaceuticals (acquired by Allergan), and Pharmion (acquired by Celgene), among others.
Prior to joining Bay City Capital, Mr. Misfeldt was a Vice President at Roth Capital Partners where he worked as a sell-side analyst covering the biopharmaceutical industry. He began his career in consulting at LifeScience Economics. Mr. Misfeldt received a BA in Economics from the University of California, San Diego.